Nrgene (NRGN) AI Stock Analysis

• Market Cap: 35.10M
• Dividend Yield: N/A
• Average Volume (3M): 37.57K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.95
• Revenue Growth: -35.05%
• EPS Growth: 36.67%
• Country: IL
• Employees: 29
• Sector: Technology
• Sector Strength: 90
• Industry: Software - Application
• EPS (TTM): -40.30
• Shares Outstanding: 13,091,577
• 10 Day Avg. Volume: 5,315
• 30 Day Avg. Volume: 37,574
• PEG Ratio: -0.15
• Price to Book (P/B): 2.53
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.54
• Enterprise Value/Market Cap: 0.28
• Enterprise Value/Revenue: 1.28
• Enterprise Value/Gross Profit: 36.68
• Enterprise Value/Ebitda: -0.66
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 47 Neutral
• Price Target: 263.00 ▼(-1.90%Downside)

The overall score reflects significant financial weaknesses, with persistent losses and liquidity issues being the most critical concerns. Technical analysis provides limited positive insights, while valuation is hampered by a negative P/E ratio. The absence of earnings call data and corporate events leaves the financial performance as the dominant factor.

Nrgene Business Overview & Revenue Model

Company Description

NRGene (NRGN) is a genomics company that specializes in leveraging advanced computational tools to enhance agricultural productivity and sustainability. The company operates within the agricultural biotechnology sector, providing solutions that enable plant breeders and researchers to optimize crop yields, improve resistance to diseases, and enhance nutritional content. NRGene's core products and services include genomic analysis, breeding solutions, and the development of customized genomic tools for various crops.

How the Company Makes Money

NRGene makes money primarily through the sale of its genomic analysis and breeding solutions to agricultural companies, research institutions, and plant breeders. The company generates revenue by providing subscription-based access to its proprietary software platforms, which enable users to analyze and interpret genomic data effectively. Additionally, NRGene earns income through collaborative projects and partnerships with agricultural firms, where they offer tailored genomic solutions to meet specific needs. These partnerships often involve long-term agreements and may include revenue-sharing models or milestone-based payments. Licensing of proprietary genomic technologies and tools to third parties also serves as a significant revenue stream for the company.

Nrgene Financial Statement Overview

Summary

Nrgene is facing significant financial challenges across income, balance sheet, and cash flow statements. Declining revenue, persistent losses, and negative cash flows highlight operational inefficiencies and liquidity risks.

Income Statement

The company has experienced a consistent decline in revenue over the past several years, with a significant decrease from $7.6M in 2019 to $1.29M in 2024. Both EBIT and net income margins are negative, indicating ongoing operational and profitability challenges. The gross profit margin has also been declining, highlighting increased cost pressures or reduced pricing power. These factors collectively suggest weak income statement performance.

Balance Sheet

The balance sheet shows a relatively stable equity base, but the debt-to-equity ratio has improved significantly from negative equity positions in earlier years to a more balanced structure in 2024. However, the equity ratio remains low, indicating a high level of liabilities relative to assets. While the company has managed to reduce total debt, the overall financial health remains fragile.

Cash Flow

The company has consistently reported negative operating and free cash flows, suggesting challenges in generating cash from core operations. The free cash flow has further declined in recent years, reflecting increased capital expenditure or reduced cash generation. The operating cash flow to net income ratio remains negative, indicating cash flow issues. Overall, cash flow performance is poor, with significant risks to liquidity.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.29M	2.00M	3.16M	4.46M	7.04M
Gross Profit	267.00K	901.00K	1.71M	2.46M	4.51M
EBITDA	-2.69M	-4.53M	-5.59M	-7.66M	-1.75M
Net Income	-3.36M	-5.24M	-6.21M	-8.34M	-3.15M
Balance Sheet
Total Assets	6.00M	10.79M	17.30M	26.36M	3.80M
Cash, Cash Equivalents and Short-Term Investments	1.37M	6.45M	12.28M	8.85M	1.48M
Total Debt	288.00K	797.00K	791.00K	3.34M	5.08M
Total Liabilities	2.00M	3.57M	5.04M	8.68M	9.33M
Stockholders Equity	3.96M	7.21M	12.26M	17.68M	-5.53M
Cash Flow
Free Cash Flow	-5.19M	-5.58M	-7.83M	-6.67M	-1.44M
Operating Cash Flow	-3.56M	-3.91M	-6.12M	-5.57M	-1.42M
Investing Cash Flow	-1.30M	-1.27M	12.47M	-14.83M	-33.00K
Financing Cash Flow	-317.00K	-410.00K	-2.46M	27.59M	326.00K

Nrgene Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 268.10
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:NRGN, the sentiment is Negative. The current price of 268.1 is above the 20-day moving average (MA) of 265.79, above the 50-day MA of 265.71, and below the 200-day MA of 298.12, indicating a neutral trend. The MACD of 0.88 indicates Negative momentum. The RSI at 50.02 is Neutral, neither overbought nor oversold. The STOCH value of 91.32 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:NRGN.

Nrgene Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ABRA	73 Outperform	539.60M	38.10		―	―	―
MTRX	73 Outperform	7.96B	28.46		262.99%	5.14%	18.71%
ONE	71 Outperform	6.24B	26.15		252.27%	10.20%	25.17%
Sector *	61 Neutral	CHF2.83B	-63.52	-3.96%	1.32%	-26.92%	-138.40%
NRGN	47 Neutral	35.10M	―		―	-35.05%	36.67%